Form
SCHEDULE 13D/A
Active or control-oriented beneficial ownership filing.
Pivotal bioVenture Partners Fund I, L.P. - 24 Feb 2026 SCHEDULE 13D/A Report for Bolt Biotherapeutics, Inc. Common Stock, $0.00001 par value (BOLT)
- Filing manager
- Pivotal bioVenture Partners Fund I, L.P.
- Reporting owner
- Nan Fung Group Holdings Limited
- Beneficially owned shares
- 87,486 shares
- Large-stake signal
-
Ownership
4.6%Beneficial ownership of this reported class.
Shares
87,486 sharesShares beneficially owned as disclosed.
Event date
24 Feb 2026Date tied to the ownership event or amendment.
Accepted by SEC
26 Feb 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 4.6%
- Symbol
- BOLT
- Shares outstanding
- 1,901,870 shares
- SEC form
- SCHEDULE 13D/A
- Accepted by SEC
- 26 Feb 2026, 19:22:05 UTC
- Event date
- 24 Feb 2026
- Prior SEC filing
- 17 Feb 2026
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
Pivotal bioVenture Partners Fund I, L.P. disclosed 4.6% ownership in Bolt Biotherapeutics, Inc. Common Stock, $0.00001 par value (BOLT) on 24 Feb 2026.
Key facts
- Pivotal bioVenture Partners Fund I, L.P. filed SCHEDULE 13D/A for Bolt Biotherapeutics, Inc. Common Stock, $0.00001 par value (BOLT).
- Disclosed ownership: 4.6%.
- Date of event: 24 Feb 2026.
Change
- Previous schedule filing date: 17 Feb 2026.
- Current filing was accepted on 26 Feb 2026, 19:22.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (11)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Nan Fung Group Holdings Limited | 4.6% | 87,486 | 0 | 87,486 | /s/ Tang Chun Wai Nelson | Tang Chun Wai Nelson, Director | 0001782539 |
| NF Investment Holdings Limited | 4.6% | 87,486 | 0 | 87,486 | /s/ Tang Chun Wai Nelson | Tang Chun Wai Nelson, Director | |
| Pivotal bioVenture Partners Fund I, L.P. | 2.7% | 52,556 | 0 | 52,556 | By Pivotal bioVenture Partners Fund I G.P., L.P. | its General Partner | 0001695076 |
| Pivotal bioVenture Partners Fund I G.P., L.P. | 2.7% | 52,556 | 0 | 52,556 | By Pivotal bioVenture Partners Fund I U.G.P., Ltd. | its General Partner | 0001752862 |
| Pivotal bioVenture Partners Fund I U.G.P. Ltd. | 2.7% | 52,556 | 0 | 52,556 | /s/ Robert Hopfner | Robert Hopfner, Authorized Signatory | |
| Pivotal Partners Ltd | 2.7% | 52,556 | 0 | 52,556 | /s/ Sun Xintong | Sun Xintong, Director | |
| Pivotal Life Sciences Holdings Limited | 2.7% | 52,556 | 0 | 52,556 | /s/ Sun Xintong | Sun Xintong, Director | |
| Nan Fung Life Sciences Holdings Limited | 4.3% | 82,486 | 0 | 82,486 | /s/ Sun Xintong | Sun Xintong, Director | |
| Permwell Management Limited | 0.3% | 5,000 | 0 | 5,000 | /s/ Tang Chun Wai Nelson | Tang Chun Wai Nelson, Director | |
| NFLS Beta Limited | 1.6% | 29,930 | 0 | 29,930 | /s/ Sun Xintong | Sun Xintong, Director | |
| NFLS Platform Holdings Limited | 1.6% | 29,930 | 0 | 29,930 | /s/ Sun Xintong | Sun Xintong, Director |
CIK / CUSIP context first